Analysis, guides and explainers on India's unlisted market — from IPO pipelines to ESOP liquidity.
<strong>Introduction</strong> Maharashtra Knowledge Corporation Limited (MKCL) has recently published its annual financial report for the fiscal year 2022-23. The report showcases significant financial growth across various metrics, including total income, revenue from operations, and profits before and after tax. This blog aims to provide a comprehensive analysis of MKCL's financial performance for the last fiscal year, focusing on key indicators that would be of interest to investors and stakeholders. <strong>Highlights of Financial Performance</strong> <strong>1. Substantial Growth in Total Income</strong> For the fiscal year 2022-23, MKCL's total income saw an impressive hike of 33.75%, standing at Rs. 20,323.90 lakhs compared to Rs. 15,195.51 lakhs in FY 2021-22. This rise represents an increase of Rs. 5,128.39 lakhs year-over-year. <strong>2. Spike in Revenue from Operations</strong> MKCL's revenue from operations for FY 2022-23 amounted to Rs. 17,750.84 lakhs, marking a 47.71% growth compared to Rs. 12,017.23 lakhs in the previous fiscal year. This represents an increase of Rs. 5,733.61 lakhs. <strong>3. Increase in Expenditure</strong> The company's total expenditure also went up by 36%, escalating from Rs. 10,404.47 lakhs in FY 2021-22 to Rs. 14,194.45 lakhs in FY 2022-23. <strong>4. Profit Metrics: Before and After Tax</strong> The PBT for the fiscal year 2022-23 stood at Rs. 6,129.45 lakhs, a 27.94% growth over last year's Rs. 4,791.04 lakhs. This increase amounts to Rs. 1,338.41 lakhs. <strong>5. Profits After Tax (PAT)</strong> MKCL's Profit After Tax for the fiscal year 2022-23 was Rs. 4,776.24 lakhs, up by 23.49% from Rs. 3,867.65 lakhs in FY 2021-22. The increase amounts to Rs. 908.59 lakhs. <img class="wp-image-26276 aligncenter" src="https://unlistedzone.com/storage/knowledge-logo/Maharashtra-Knowledge-Corporation-Limited.jpeg" alt="" width="619" height="365" /> <strong>Balance Sheet Indicators</strong> <strong>1. Growth in Total Assets and Liabilities</strong> Both the total assets and the total equity and liabilities of MKCL increased by 12%, each reaching Rs. 55,929.75 lakhs compared to Rs. 49,835.48 lakhs in the previous fiscal year. <strong>Cash Flow Statement Insights</strong> <strong>1. Cash Generated from Operating Activities</strong> The net cash generated from operating activities was Rs. 4,538.23 lakhs, a significant improvement over the cash used of Rs. (569.37) lakhs in FY 2021-22. <strong>2. Cash Used in Investing and Financial Activities</strong> The company used Rs. 4,273.92 lakhs in investing activities and Rs. (327.04) crore in financial activities during FY 2022-23, compared to Rs. (694.50) crore and Rs. (103.84) crore, respectively, in the previous year. <strong>Conclusion</strong> MKCL's financial performance in FY 2022-23 reflects a robust growth trajectory across various financial metrics. The company has shown an admirable ability to increase revenues while effectively managing expenditures. The significant upticks in PBT and PAT further highlight the company's profitability. With a stable balance sheet and positive cash flow from operating activities, MKCL appears well-positioned for future growth. These factors make it an entity worth considering for investors looking for sustainable and profitable investment opportunities. https://unlistedzone.com/shares/buy-sell-share-price-maharashtra-knowledge-corporation-mkcl-limited-unlisted-shares/
<h3>1. Steps taken to improve Profitability by Pharmeasy in Fy23</h3> <p>a) Marketing and growth expenses are reduced as a % of revenue from 7.9% in FY’22 to 3.3% in FY’23, with Q4’23 at 0.6% of revenue. It means total reduction of INR ~504 Cr in Fy22 to INR ~201 Cr in FY23. <br /><br />b) EBITDA margins (normalised) improved from -13.6% in FY22 to -8.4% in FY23 and 1.6% in three months ended June 2023. <br /><br />c) Increasing share of margin accretive private label in our products business from 0.7% to 1.4% during this period from FY22 to FY23. <br /><br />d) They are now focussing on investing significantly in enhancing their cross-sell capabilities to offer high margin services to customers across the businesses. e) Significant savings were realized on our employee benefit expenses as we brought synergies across multiple acquired business by consolidating team and streamlining organisation structure.</p> <h3>2. Pharmeasy Interesting Facts in Fy23</h3> <p>a) On the PharmEasy marketplace, the diagnostics business expanded due to cross-sell strategy. In Fiscal 2023, 50 lacs customers, or 13.8% of total PharmEasy consumers, used their diagnostic services. <br /><br />b) Thyrocare business has now fully recovered from the Covid led sectoral growth in FY21 & FY22 and is now growing its non-covid business. Thyrocare revenue & sample growth of non-covid business has grown +22% (non-covid revenue growth), +39% (sample growth) YoY in FY23.<br /><br /><img class="alignnone wp-image-26255" src="https://unlistedzone.com/storage/knowledge-logo/Screenshot-2023-08-23-at-4.02.04-PM.png" alt="" width="735" height="313" /></p> <h3>3. Revenue and Variable Expenses of Pharmeasy in Fy22, Fy23 and Q1Fy24</h3> <p><img class="alignnone wp-image-26250" src="https://unlistedzone.com/storage/knowledge-logo/WhatsApp-Image-2023-08-23-at-15.27.43.jpeg" alt="" width="730" height="424" /> <img class="alignnone wp-image-26251" src="https://unlistedzone.com/storage/knowledge-logo/WhatsApp-Image-2023-08-23-at-15.33.18.jpeg" alt="" width="732" height="425" /> <br /><br />a) The revenue has increased by 5% from INR 6381 Cr in Fy22 to INR 6702 Cr in Fy23. Revenue from sale of goods increased by 6.8% to INR 5983 Cr in Fiscal 2023 from INR 5600 Cr in Fiscal 2022. All segments reported growth in FY22 and FY23, except for sale to Retailers, which grew in FY22 by about 52.7% but declined in FY23 by 19.3%. The historical growth was mainly due to increased marketing in FY22, which was reduced in FY23. The drop in FY23 sales to Retailers resulted from Management's strategy to prioritize profitability, disincentivizing low-value orders, and cutting marketing spends. This affected the Retailer segment, but there was growth in the chemists and hospitals network for other products. <br /><br />b) Pharmeasy has significantly reduced the Sales and Promotion expenses by 281 Cr in Fy23. Overall, Other expenses have reduced from INR 1566 Cr in FY22 to INR 938 Cr in FY23. Reduction of 40%.<br /><br />c) The Contribution margin ( Revenue - Variable Cost ) has improved slightly from INR 316 Cr in FY22 to INR 389 Cr in Fy23. <br /><br />d) However, still due to high Sales and Administration expenses Pharmeasy is in losses. The losses has however, reduced considerably from 3970 Cr in Fy22 to 2283 Cr in Fy23.</p> <h3>4. Capital Structure and Total Outstanding Shares of Pharmeasy</h3> <p>a) As on 31.03.2023, they have ~614 Cr Equity Shares and ~5.48 Cr Series A CCPS outstanding. b) These ~5.48 Cr Series A CCPS were issued via Right Issue in Sept and Nov-22, in three tranches at INR 100 per share thereby raising ~548 Cr. However, the conversion formula for these Series A CCPS into equity shares is as below. <img class="alignnone wp-image-26252" src="https://unlistedzone.com/storage/knowledge-logo/Screenshot-2023-08-23-at-4.14.14-PM.png" alt="" width="535" height="164" /> <br /><br /><strong>Pharmeasy's Right Issue Details:</strong> <br /><br />a) Pharmeasy is planning to raise approximately INR 3500 Cr through a Right Issue. b) The price per share for the Right Issue is set at Rs.4.84. c) The company will issue around ~723 Cr Series B CCPS. <br /><br /><strong>Conversion Details for Right Issue done by Pharmeasy in Sept and Nov-22</strong> <br /><br />a) Investors who participate in the Right Issue at Rs.100 will undergo a conversion process for their shares. <br /><br />b) The Conversion Price is calculated as:</p> <div class="math math-display"><img class="alignnone wp-image-26254" src="https://unlistedzone.com/storage/knowledge-logo/Screenshot-2023-08-23-at-4.27.53-PM.png" alt="" width="748" height="124" /></div> <p>c) With this conversion price, for every 1 Series A CCPS, investors will receive 21 Equity Shares. d) As a result, the initial ~5.48 Cr shares will be converted into ~115.08 Cr shares. <br /><br /><strong>Total Shares Post Right Issue:</strong> <br /><br />a) After the Right Issue and conversion, the total shares outstanding will be:</p> <div class="math math-display"><span class="katex-display"><span class="katex-display"><span class="katex"><span class="katex-mathml">b) Total Shares=614 Cr+115 Cr+723 Cr= 1452 Cr. <br /><br />( <strong>Please note</strong>: <em>We have not taken into Account the Anti-Dilutive rights of Shares held by investors in different classes prior to conversion to Equity Shares before IPO</em> ).</span></span></span></span> <h3>5. Valuation of Pharmeasy</h3> Currently, in the unlisted market the Pharmeasy Unlisted Share Price is INR 15 per share. Mcap = 15*1452 = ~21000 Cr ( Current Unlisted Market Price) = $2.6 Billion Mcap = 5*1452 = 7260 Cr ( Current Right Issue Market Price ) = $0.90 Billion <h3>6. Conclusion</h3> "The growth of Pharmeasy in FY23 has slowed down a bit. The primary reason for this is their retail business, where they have reduced marketing expenses and discounts. There has been a 20% decline in the retail sector and a 20% decline in the diagnostic business. On the other hand, there has been a growth of 16% in the distribution to chemists and 33% in the hospital business. Overall, looking at FY23, it seems to have been a year of consolidation for the company. Rather than focusing on growth, the company has emphasized profitability. This approach has reduced their loss from ~4000 Cr in FY22 to ~2200 Cr in FY23. In addition, they have aligned the operations of many of their businesses and have undertaken cost-cutting measures. If the proposed rights issue is successful, Pharmeasy will have the funds necessary for survival. The most significant advantage will be that they won't have to sell any of their businesses. As the company is focusing on reducing expenses, there's hope that in the next 2-3 years, the company might become profitable."</div>
<h4>1. About Arohan Financials</h4> Arohan is a leading, digitally advanced, NBFC-MFI, regulated by the Reserve Bank of India. Headquartered in Kolkata, the Company is present in 17 states spanning rural, semi-urban, and urban geographies in India catering to the bottom of the socio - economic pyramid through a range of financial inclusion products. <h4>2. Key Performance Indicator in Fy23</h4> <img class="alignnone size-full wp-image-26239" src="https://unlistedzone.com/storage/knowledge-logo/Screenshot-2023-08-21-at-5.34.31-PM.png" alt="" width="2406" height="988" /> <h4>3. Updates on Business of Arohan Financials in Fy23</h4> a) During the year, total disbursed loans amounting to approximately INR 5300 Cr, which helped millions of families in starting their own businesses, pay for their children’s education, build their own homes, or meet their medical expenses. b) They have dedicated to upholding top-tier corporate governance standards and have introduced 'Nirnay', their credit scoring system, using data analytics to evaluate client creditworthiness and reduce chances of NPA. c) In Fy22-23, they started operations in Rajasthan, Haryana, and Uttarakhand. To serve the 'missing middle' segment, Arohan hs introduced Micro-Enterprise Loans under its 'Bazaar' product, with loan amounts between INR 1,05,000 and INR 1,50,000. d) In April 2023, Arohan Financial secured one of the sector's largest fund raises of over INR 730 Cr, with four new investors backing the management and business model. This funding is raised INR 85 per share. e) In FY 2023, they have opened about 100 branches, totaling 829 by March 31, 2023. Arohan plans to expand into Gujarat and Maharashtra by establishing branches in adjacent regions. <h4>4. Financials Performance of Arohan Financials in Fy23</h4> <table dir="ltr" border="1" cellspacing="0" cellpadding="0"><colgroup> <col width="172" /> <col width="100" /> <col width="100" /></colgroup> <tbody> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"Particulars (in Cr)"}">Particulars (in Cr)</td> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"FY23"}">FY23</td> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"FY22"}">FY22</td> </tr> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"Net Interest Income"}">Net Interest Income</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":931}">931</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":859}">859</td> </tr> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"Other Income"}">Other Income</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":21}">21</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":19}">19</td> </tr> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"Total Income"}">Total Income</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":1091}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}">1,091</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":920}">920</td> </tr> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"Operational Cost"}">Operational Cost</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":804}">804</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":696}">696</td> </tr> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"Profit Before Provisioning"}">Profit Before Provisioning</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":287}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}" data-sheets-formula="=R[-2]C[0]-R[-1]C[0]">287</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":224}" data-sheets-formula="=R[-2]C[0]-R[-1]C[0]">224</td> </tr> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"Provisioning"}">Provisioning</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":193}">193</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":135}">135</td> </tr> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"Profit After Provisioning"}">Profit After Provisioning</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":94}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}" data-sheets-formula="=R[-2]C[0]-R[-1]C[0]">94</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":89}" data-sheets-formula="=R[-2]C[0]-R[-1]C[0]">89</td> </tr> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"PBT"}">PBT</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":90}">90</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":83}">83</td> </tr> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"Tax"}">Tax</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":19}">19</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":22}">22</td> </tr> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"PAT"}">PAT</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":71}" data-sheets-formula="=R[-2]C[0]-R[-1]C[0]">71</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":61}" data-sheets-formula="=R[-2]C[0]-R[-1]C[0]">61</td> </tr> </tbody> </table> <table dir="ltr" border="1" cellspacing="0" cellpadding="0"><colgroup> <col width="145" /> <col width="100" /> <col width="100" /></colgroup> <tbody> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"Particulars (in Cr)"}">Particulars (in Cr)</td> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"FY23"}">FY23</td> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"FY22"}">FY22</td> </tr> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"Loan Book "}">Loan Book</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":4782}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}">4,782</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":3710}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}">3,710</td> </tr> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"Revenue"}">Revenue</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":1091}" data-sheets-numberformat="{"1":2,"2":"#,##0","3":1}">1,091</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":920}" data-sheets-formula="=R[1]C[-4]">920</td> </tr> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"PAT"}">PAT</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":71}">71</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":61}">61</td> </tr> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"NIM"}">NIM</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":0.096}" data-sheets-numberformat="{"1":3,"2":"0.00%","3":1}">9.60%</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":0.134}" data-sheets-numberformat="{"1":3,"2":"0.00%","3":1}">13.40%</td> </tr> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"ROA"}">ROA</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":0.011797939514788967}" data-sheets-numberformat="{"1":3,"2":"0.00%","3":1}" data-sheets-formula="=R[-2]C[0]/6018">1.18%</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":0.011665710460891184}" data-sheets-numberformat="{"1":3,"2":"0.00%","3":1}" data-sheets-formula="=R[-2]C[0]/5229">1.17%</td> </tr> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"Gross NPA"}">Gross NPA</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":0.028}" data-sheets-numberformat="{"1":3,"2":"0.00%","3":1}">2.80%</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":0.045}" data-sheets-numberformat="{"1":3,"2":"0.00%","3":1}">4.50%</td> </tr> <tr> <td style="text-align: center;" data-sheets-value="{"1":2,"2":"Net NPA"}">Net NPA</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":0.0021}" data-sheets-numberformat="{"1":3,"2":"0.00%","3":1}">0.21%</td> <td style="text-align: center;" data-sheets-value="{"1":3,"3":0.0132}" data-sheets-numberformat="{"1":3,"2":"0.00%","3":1}">1.32%</td> </tr> </tbody> </table> <h4>5. Valuation of Arohan Financials</h4> (i) As on 31.03.2023, total shares outstanding is ~15 Cr and total Net-worth is ~1340 Cr. (ii) Book Value = 1340/15 = INR 89 per share (iii) Arohan Financials Unlisted Share Price ( as on 21.08.2023 ) = INR 160 per share (iv) P/B = 1.74x which in line with other listed peers in the market. https://unlistedzone.com/shares/arohan-financial-services-unlisted-shares/
<strong>1. About Carrier Air Conditioning Unlisted Share Business</strong> Carrier Air Conditioning is a pioneer in the HVAC industry, dedicated to providing high-quality air conditioning solutions to its customers. With a rich history of innovation and commitment to sustainability, Carrier continuously strives to enhance comfort and air quality in homes, offices, and larger commercial spaces. <strong>2. Carrier Air Conditioning Unlisted Share Highlights of 2023 Financial Results:</strong> <strong>a) Revenue from Operations:</strong> There's been an impressive growth in revenue from 2022 to 2023. The figures jumped from ₹1,612 Cr in 2022 to ₹2,197 Cr in 2023, marking a growth of approximately 36%. <strong>b) EBITDA:</strong> EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) saw more than a two-fold increase, from ₹63 Cr in 2022 to ₹141 Cr in 2023. This reflects a stronger operational performance. <strong>c) PAT Growth:</strong> The Profit After Tax (PAT) figures speak for themselves. A growth from ₹42 Cr in 2022 to ₹110 Cr in 2023 indicates a substantial enhancement in profitability, showing an impressive 162% increase year-on-year. <strong>3. Valuation Insights</strong> With the current market price of the share being ₹325, and an Earnings Per Share (EPS) of ₹10.3 for 2023, the Price-to-Earnings (P/E) of 31x. <strong>4. Investment Opportunity</strong> To all our readers and investors, Carrier Air Conditioning is showing promising growth and robust financial health. If these figures have piqued your interest, you can delve deeper and buy these shares exclusively from the www.UnlistedZone.com platform. Don't miss this opportunity to invest in a company that's making strides in the HVAC industry! https://unlistedzone.com/shares/buy-sell-share-price-carrier-airconditioning-refrigeration-unlisted-shares/
<h3>1. History of NSE:</h3> <p>The National Stock Exchange of India Limited (NSE) was established in 1992, commencing operations in 1994. It was set up to introduce transparency into the Indian equity market. Before NSE's inception, trading on the stock exchange in India was primarily conducted via open outcry, primarily at the Bombay Stock Exchange (BSE). NSE brought about a significant transformation by introducing a fully automated screen-based electronic trading system.</p> <hr /> <h3>2. Revenue Sources of NSE:</h3> <p>The NSE has diversified revenue streams: <br /><br /><strong>a) Trading Fees:</strong> Revenue generated from the buying and selling of securities. <br /><br /><strong>b) Listing Fees:</strong> Income from companies that opt to list their shares on the exchange. <br /><br /><strong>c) Data Feed Fees:</strong> Earnings from selling market data to entities like brokers, institutions, etc. <br /><br /><strong>d) Membership Registration and Annual Fees:</strong> From its registered brokers. <br /><br /><strong>e) Depository Services:</strong> Through its subsidiary, NSDL. <br /><br /><strong>f) Clearing and Settlement Fees:</strong> Revenue from these vital services. A significant portion, 80% to be precise, of NSE's revenue is derived from trading fees. The revenue distribution is further categorized based on the trading of various products. <br /><br /><img class="alignnone wp-image-26214" src="https://unlistedzone.com/storage/knowledge-logo/Screenshot-2023-08-18-at-2.46.04-PM.png" alt="" width="357" height="247" /></p> <hr /> <h3>3. Top Investors in NSE Unlisted Share:</h3> <p>Prominent stakeholders in the NSE include: <br /><br /><img class="alignnone wp-image-26215" src="https://unlistedzone.com/storage/knowledge-logo/Screenshot-2023-08-18-at-2.55.36-PM.png" alt="" width="559" height="318" /></p> <hr /> <h3>4. Five years Revenue Growth of <a href="https://unlistedzone.com/shares/nse-india-limited-unlisted-shares/">NSE Unlisted Share</a>:</h3> <p>From 2019 to 2023, NSE exhibited a significant growth trajectory: <br /><br /><strong>a) 2019:</strong> Total Revenue of 3,514 Crores <br /><br /><strong>b) 2020:</strong> Total Revenue of 3,896 Crores <br /><br /><strong>c) 2021:</strong> Total Revenue of 6,202 Crores <br /><br /><strong>d) 2022:</strong> Total Revenue of 9,500 Crores <br /><br /><strong>e) 2023:</strong> Total Revenue of 11,586 Crores This indicates a robust growth rate, especially in the years post-2020.</p> <hr /> <h3>5. NSE vs BSE Comparison:</h3> <p><strong>a) Market Capitalisation:</strong> <br /><br />(i) NSE: 1.80 Lakh Crores (ii) BSE: 11,000 Crores <br /><br /><strong>b) P/E Ratio:</strong> <br /><br />(i) NSE: 24x (ii) BSE: 44x <br /><br /><strong>c) Revenue (Fy23):</strong> <br /><br />(i) NSE: 12,000 Crores (ii) BSE: 990 Crores <br /><br />The comparison showcases that while NSE has a much larger market capitalisation and revenue than BSE, its P/E ratio is nearly half, indicating better earnings relative to its share price.</p> <hr /> <h3>6. Valuation of NSE Unlisted Shares</h3> <p>The <a href="http://www.unlistedzone.com/">NSE Unlisted Shares</a> are currently available at UnlistedZone priced at INR 3,600 per share. This price gives it a market capitalization of 1.76 Lakh Crores and a P/E ratio of 24x. This valuation, when compared to its performance metrics and growth trajectory, indicates a strong and stable financial position for NSE.</p> <hr /> <h3>7. How to Buy NSE Unlisted Shares?</h3> <p>NSE shares are unlisted, meaning they aren't publicly traded on any stock exchange. Interested investors can purchase "Unlisted shares of NSE as they are accessible through <a href="http://www.unlistedzone.com">UnlistedZone</a>. For purchase inquiries, please reach out us at <a href="Mailto:[email protected]">[email protected]</a>. It's crucial to exercise caution and conduct thorough research before buying unlisted shares due to potential risks such as lack of liquidity and transparency.</p> <hr /> <h3>8. FAQs on NSE Unlisted Shares:</h3> <p>Q1: What's the latest price for NSE Unlisted shares in India? <br /><br />Answer: As of now, <a href="https://qr.ae/prfddi">NSE unlisted shares</a> are priced at Rs. 3,600 each at UnlistedZone Platform. <br /><br />Q2: What's the procedure to purchase NSE Unlisted shares in India? <br /><br />Answer: Acquiring NSE unlisted shares involves a two-stage process that spans approximately 2 months. <br /><br />The two stages are: <br /><br />a) Name Clearance <br /><br />b) Credit of Shares. <br /><br />Notably, the NSE board has recently expedited this process, leading to quicker share transfers. <br /><br />Q3: On what basis is the NSE unlisted shares price set? <br /><br />Answer: In the short term, the price of <a href="https://unlistedzone.com/shares/nse-india-limited-unlisted-shares/">NSE unlisted shares</a> is primarily influenced by market demand and supply. Over the long term, the company's fundamentals play a pivotal role in determining the price. <br /><br />Q4: How secure is it to transact NSE unlisted shares in India? <br /><br />Answer: Engaging in transactions of NSE Unlisted shares always carries inherent risks. Yet, these risks can be significantly reduced when dealing through a reputable platform like <a href="http://www.unlistedzone.com">UnlistedZone.</a> <br /><br />Q5: How can I monitor the price of NSE unlisted shares? <br /><br />Answer: With UnlistedZone, it's convenient to stay updated on unlisted share prices. By downloading our app from the Play-store and completing the registration, you'll gain access to the latest news, videos, and insights on NSE on a regular basis.</p> <hr /> <h3>Conclusion:</h3> <p>The NSE has showcased strong growth, particularly in recent years, and holds a dominant position in the Indian securities market. Its diversified revenue streams, along with the backing from prominent investors, position it as a key player in the industry. The valuation suggests that it's a significant entity in the financial world, and its comparison with BSE further cements its dominant position. As always, potential investors should conduct their due diligence and consult with financial professionals before making investment decisions.</p>
The Burman family, well-known for their affiliation with the renowned ayurvedic brand Dabur, reportedly made a notable move on August 16th. Through a block deal, they acquired an additional 5 percent stake in Religare Enterprises. This strategic decision served to elevate their ownership percentage in the company from the previously recorded 14 percent, a figure noted in the month of June. Apart from their involvement with Dabur, the Burman family also has a good amount of shares in Religare Enterprises through different parts of their business. Religare Enterprises is a part of Religare Finvest (RFL). They want to get Rs 800 crore by asking big investors for money, and they're doing this through something called a qualified institutional placement (QIP). They managed to sort out their financial issues with lenders from Religare Finvest Ltd by making a single settlement. To settle everything, they paid Rs 400 crore to 16 lenders in March this year. [Source: Moneycontrol] https://unlistedzone.com/shares/care-health-previously-religare-health-insurance-company-limited-unlisted-shares-buy-sell-share-price
<p><strong>Introduction:</strong> <br /><br />The Indian financial landscape is abuzz with the imminent IPO of Hero FinCorp, the finance arm of the iconic two-wheeler manufacturer, Hero MotoCorp. With talks about raising a massive Rs. 4,000 crore, this move is set to make waves in the industry. <br /><br /><strong>Ownership Dynamics</strong> <br /><br />The ownership blend of Hero FinCorp is both intriguing and balanced. With Hero MotoCorp boasting a 40% stake and the influential Munjal family holding 30%, the entity carries a legacy. The rest is spread amongst industry giants such as ChrysCapital, Apollo Global, Credit Suisse, and Apis Partners, signifying trust and robust collaboration. <br /><br /><strong>Impressive Track Record:</strong> <br /><br />Financial Year 2022-23 was a landmark for Hero FinCorp. With an interest income reaching Rs. 5,363 crore and a net profit touching Rs. 457 crore, the company has established itself as a force to reckon with. Its loan portfolio, standing at an imposing Rs. 36,000 crore, testifies to its financial acumen and market penetration. <br /><br /><strong>A Look into the Past</strong> <br /><br />Hero FinCorp, originally Hero Finlease, traces its roots back to the era when it was the primary financier for Hero Honda. Post the restructuring of Hero Honda Motors in 2011, the company reinvented itself, marking a phase of robust expansion. This journey saw them diversify into two-wheeler financing and then venturing into SME and corporate financing. The icing on the cake was the acquisition of a housing finance business license in 2017, further expanding their portfolio. <br /><br /><strong>Steering the Ship</strong> <br /><br />Under the visionary leadership of Pawan Munjal, both Hero MotoCorp and Hero FinCorp have witnessed remarkable growth. With revenues of Rs. 8,767 crore for the quarter ending June 30 of the current fiscal year and a YoY growth of 4.5%, their trajectory seems unstoppable. <br /><br /><strong>Current Market Scenario:<br /><br /></strong> In the prevailing unlisted market, Hero FinCorp shares are trading at Rs. 1,200 each, resulting in a market cap of approximately Rs. 14,820 crore. This valuation closely aligns with the anticipated IPO pricing, making it a noteworthy consideration for potential investors. <strong>Conclusion:</strong> Hero FinCorp's impending IPO is not just about numbers, but about a legacy, trust, and a vision for the future. For those closely observing the financial markets, this is an event to watch out for.</p> <p><a href="https://unlistedzone.com/shares/hero-fincorp-limited-share-price-buy-sell-unlisted-shares-of-hero-fincorp/">https://unlistedzone.com/shares/hero-fincorp-limited-share-price-buy-sell-unlisted-shares-of-hero-fincorp/</a></p> <p> </p>
Mohan Meakin, a renowned name in the industry, has recently unveiled its Q1FY24 results. Let's delve deeper into the numbers and uncover the story they tell. <strong>1. Sales:</strong> The company reported sales of 305 Cr in Q1FY24, a decrease from 344 Cr in Q1FY23. This represents a reduction of roughly 11.3%. <strong>2. Cost of Material Consumed:</strong> There has been a significant reduction in the cost of materials consumed, down from 54 Cr in Q1FY23 to 39 Cr in Q1FY24, which indicates improved cost management. <strong>3. Purchase of Stock:</strong> Mohan Meakin increased its stock purchases to 154 Cr in Q1FY24 from 119 Cr in Q1FY23, marking an increase of 29.4%. This could be a sign of anticipation of higher sales in the upcoming quarters or better deals from suppliers. <strong>4. Excise Duty:</strong> A significant drop in excise duty from 132 Cr in Q1FY23 to 73 Cr in Q1FY24 can be seen, which either indicates regulatory changes or a decrease in sales volume in categories with high excise duties. <strong>5. Operating Profit Margin (OPM):</strong> The OPM increased from 2.03% in Q1FY23 to 3.93% in Q1FY24. This upward shift of almost 2% points towards better operational efficiency. <strong>6. Profit After Tax (PAT):</strong> The company's PAT witnessed a commendable increase, moving from 4 Cr in Q1FY23 to 9 Cr in Q1FY24. <strong>7. Net Profit Margin (NPM):</strong> The NPM also saw an upward trend, increasing from 1.16% in Q1FY23 to 2.93% in Q1FY24. This indicates that the company has been able to retain a larger portion of its revenue as profit. <strong>8. Earnings Per Share (EPS):</strong> Shareholders would be pleased to see the EPS almost doubling from 6.00 in Q1FY23 to 11.00 in Q1FY24. <strong>Conclusion</strong> Mohan Meakin's Q1FY24 results portray a tale of resilience and strategic growth. Despite a dip in sales, the company has managed to improve its operational efficiency, resulting in better profit margins. The sharp increase in EPS is a testament to the management's commitment to delivering value to its shareholders. The road ahead looks promising for Mohan Meakin. It will be interesting to see how the company capitalizes on these results in the upcoming quarters. Disclaimer: This blog is for informational purposes only and should not be considered as financial advice. Investors are advised to do their own research or consult with a financial advisor before making any investment decisions. https://unlistedzone.com/shares/mohan-meakin-limited-share-price-buy-sell-mohan-meakin-unlisted-shares/
<strong>Introduction</strong> Indian digital wallet major, MobiKwik, recently unveiled its financial results for the June quarter of 2023, setting the tone for its stellar performance in the ongoing fiscal year. The figures hint at a promising trajectory, marking significant milestones for the company. <strong>Robust Financial Growth:</strong> Highlighting a surge of 181% year-on-year, MobiKwik reported an adjusted Ebitda of Rs. 13.6 crore. It is worth noting that this is the second consecutive quarter where the company has witnessed a substantial profitable growth. The icing on the cake? MobiKwik recorded its first-ever consolidated profit during this period, ringing in at Rs. 3 crore. <strong>Revenue Uptrend</strong> The revenue figures presented by the firm stand as a testament to its growth strategy. Clocking in at Rs. 177 crore, the revenue reflects a whopping 68% year-on-year growth. To put this into perspective, the previous quarter's (March) revenue was pegged at Rs. 160 crore. <strong>Soaring Contribution Margin:</strong> Yet another impressive metric, the contribution margin skyrocketed with a 108% surge, settling at Rs. 73.9 crore for the June quarter. A comparative view paints an even brighter picture, considering that in FY22, the margin was a mere Rs. 42 crore. Fast forward to FY23, and it elevated to a staggering Rs. 169.5 crore, a year-on-year increase of nearly 304%. <strong>MobiKwik's Visionary Path:</strong> Bipin Preet Singh, co-founder & CEO of MobiKwik, expressed his optimism regarding the company's trajectory. He commented, "Our vision for FY 2023-24 is to achieve profitability in all quarters. Q1 has been a good start to the fiscal year. Our numbers are positive in all parameters, and we expect to deliver a topline growth of more than 80% for this fiscal year." <strong>Looking Forward:</strong> With such strong financial momentum, MobiKwik sets its eyes on even loftier goals. The firm aims to secure a net profit ranging between Rs. 40 to Rs. 50 crore in the ongoing year, building on its legacy of exponential growth. https://unlistedzone.com/shares/buy-sell-latest-price-mobikwik-unlisted-shares/
<p><strong>Introduction</strong> <br /><br />India's power transmission sector is witnessing a wave of innovative business strategies aimed at enhancing business models and value optimization. One such player is Sterlite Power, supported by Vedanta Group's Anil Agarwal, which is currently undergoing an internal restructuring exercise. With Singapore's sovereign wealth fund, GIC, on the verge of a significant investment, all eyes are on the evolving dynamics of this deal. <br /><br /><strong>The Blueprint of Sterlite Power's Restructuring and GIC's Role</strong> <br /><br />In a strategic move, Sterlite Power is demerging its solutions business from its overall structure. This division provides strategic enhancements and upgrade solutions to power utilities. The plan for the demerged entity involves potential listing on domestic exchanges, an initiative to unlock additional value. In parallel, GIC is charting a substantial entry into Sterlite Power's power transmission business. Post the spin-off, GIC intends to invest approximately $300 million, forming a 51:49 joint venture with Sterlite Power. <br /><br /><strong>Advising the Deal: Avendus Capital and Deutsche Bank</strong> <br /><br />Avendus Capital and Deutsche Bank are key advisers in this transformational deal. While Avendus Capital is guiding Sterlite Power on the restructuring, Deutsche Bank is focusing on the GIC funding aspect. The talks are at an advanced stage and are projected to conclude soon. <br /><br /><strong>Sterlite Power's Solutions Vertical: An Overview</strong> <br /><br />The solutions vertical, earmarked for demerger, provides bespoke solutions for brownfield transmission infrastructure projects' upgrade/uprate. These strategic solutions aim to improve short and long-term performance and hold significant value within Sterlite Power's portfolio. <br /><br /><strong>The Draw for GIC: Sterlite Power's Global Infrastructure Business</strong> <br /><br />GIC's interest lies primarily in Sterlite Power's Global Infrastructure business. This sector bids for, designs, constructs, owns, and operates power transmission assets, boasting operations in India and Brazil. The division holds a portfolio of 31 completed and under-construction projects, making it a key draw for investors. <br /><br /><strong>Sterlite Power's Unlisted Shares and Future Valuation</strong> <br /><br />Currently, Sterlite Power's unlisted share price stands at Rs.600 per share. With approximately 12 Cr shares outstanding, the current valuation of the transmission business and solutions business is about Rs.7200 Cr. The value the solutions business will command post the demerger will significantly influence Sterlite Power's valuation in the unlisted market going forward. <br /><br /><strong>India's Power Transmission Infrastructure Sector: A Look Ahead</strong> <br /><br />The future seems promising for India's power transmission infrastructure sector. With expected government bids for projects worth Rs 1.50 lakh crore over the next 18 months, a robust growth phase is on the horizon. <br /><br /><strong>Conclusion</strong> <br /><br />The unfolding Sterlite Power and GIC deal paints a dynamic picture of investment and restructuring in India's power transmission sector. With potential implications for Sterlite Power's unlisted share prices, this development holds industry-wide significance and is a testament to the sector's future potential <em>Source: MoneyControl</em> https://unlistedzone.com/shares/sterlite-power-transmission-limited-share-price-buy-sell-unlisted-shares-of-sterlite-power-transmission/</p>
<h3>Introduction:</h3> <p>Sterlite Power, a key player in India's power sector, has recently announced its acquisition of the Fatehgarh III Beawar Transmission Limited from PFC Consulting Limited, marking its 18th project under the tariff-based competitive bidding (TBCB) process mode. This significant move underscores Sterlite Power's growing influence in the Indian energy landscape.</p> <h3>Project Overview:</h3> <p>The acquisition involves the development of a 350km, 765kV transmission corridor stretching from Fatehgarh III to Beawar in Rajasthan. This project, awarded by PFC Consulting Limited—a wholly-owned subsidiary of the Maharatna enterprise Power Finance Corporation Limited (PFC)—through a TBCB process in March 2023, represents a major step in enhancing the region's power infrastructure.</p> <h3>Sterlite Power’s Role and Responsibilities:</h3> <p>Under this acquisition, Sterlite Power will undertake the construction, ownership, operation, and eventual transfer of this crucial transmission project. The project's tenure extends to a substantial 35-year period, reflecting its long-term strategic importance.</p> <h3>Impact on Renewable Energy:</h3> <p>This project is pivotal for the evacuation of a significant portion of 20 GW of renewable power from the Renewable Energy Zones in Fatehgarh (9.1 GW), Bhadla (8 GW), and Ramgarh (2.9 GW) areas of Rajasthan. This aligns with India's broader objectives in renewable energy development.</p> <h3>Statement from Sterlite Power:</h3> <p>Pratik Agarwal, the Managing Director of Sterlite Power, emphasized the role of green energy corridors in India’s nation-building efforts. He remarked, “These corridors are essential for India to reach its ambitious renewable energy goal of 500 GW by 2030. With Sterlite Power's specialized capabilities and expertise, we are fully committed to contributing to this monumental endeavor."</p> <h3>Conclusion:</h3> <p>Sterlite Power's acquisition of the Fatehgarh III Beawar Transmission project from PFC Consulting Limited not only expands its portfolio but also plays a crucial role in advancing India’s renewable energy vision. This move is a testament to Sterlite Power’s commitment to enhancing the nation's energy infrastructure and supporting sustainable energy goals.<br /><br /><a href="https://unlistedzone.com/shares/sterlite-power-transmission-limited-share-price-buy-sell-unlisted-shares-of-sterlite-power-transmission/">https://unlistedzone.com/shares/sterlite-power-transmission-limited-share-price-buy-sell-unlisted-shares-of-sterlite-power-transmission/</a></p> <p> </p>
Philips India Limited has announced its annual report for the financial year 2023. Philips India Limited is primarily involved in the manufacturing of Health System Machines (MRIs, CT Scan, Digital X-ray), Personal Care (Trimmer, Hair Dryer), domestic appliances (iron, juicers, food processor) and Innovation center. The company has a manufacturing plant in Pune and a software development center in Bengaluru. <strong>Financial Takeaways</strong> As per the report here are key financial highlights for FY23 compared to FY22: <strong>1. Total Revenue:</strong> In FY23, the Company's total revenue from operations increased by 5% to Rs. 5734 crore as against Rs. 5481 crore in FY22. <strong>2. Total Expenses:</strong> During FY23, the total expenses of the Company also increased by 3% to Rs. 5485 crore as against Rs. 5312 crore in FY22. <strong>3. Profit Before Tax:</strong> The profit before tax of the Company in FY23 increased by an impressive 42% to Rs. 320 crore as against Rs. 233 crore in FY22. <strong>4. Profit After Tax:</strong> However, in FY23, the profit after tax of the Company decreased by 2% to Rs. 260 crore as against Rs. 265 crore in FY22. <strong>5. Earnings Per Share (EPS):</strong> The earnings per share in FY23 (basic and diluted) of the Company dropped marginally to Rs. 45.21 as against Rs. 46.23 in FY22. 6. Total Assets: In FY23, the total assets of the Company decreased significantly by 25% to Rs. 3240 crore as against Rs. 4344 crore in FY22. <strong>7. Total Equity and Liabilities:</strong> Simultaneously, the total equity and liabilities of the Company also dropped by 25% to Rs. 3240 crore as against Rs. 4344 crore in FY22. <strong>8. Net Cash from Operating Activities:</strong> The net cash generated from operating activities of the Company in FY23 was Rs. 341 crore as against Rs. 131 crore in FY22. <strong>9. Net Cash from Investing Activities:</strong> The net cash used in investing activities of the Company in FY23 was Rs. 52 crore as against Rs. 368 crore cash generated in FY22. <strong>10. Net Cash from Financial Activities:</strong> The net cash used in financial activities of the Company in FY23 was Rs. 1392 crore as against Rs. 115 crore in FY22. <strong>Business Takeaways</strong> 1. During the year 2022-23, the Health Systems business of the Company faced headwinds due to the global macro-economic scenario, resulting in a high single-digit de-growth in the addressable market compared to the previous year. 2. The pandemic led to an acute increase in healthcare needs, providing strong tailwinds to the industry. 3. The Company strategically navigated through challenges posed by inflation, adverse currency fluctuation, and supply chain disruptions. 4. Despite the headwinds, the Company maintained its market share by leveraging strong relationships with strategic key accounts, multi-modality deals, long term contracts, and winning Government tenders. 5. The launch of MR 5300 in 2021 solidified the Company's position as the only player with a Wide Bore, Helium-free system catering to the needs of bariatric patients and addressing the global helium shortage. 6. Several new products were introduced during the year, including the expansion of General Care Solution with the new IntelliVue Guardian Software App, MR 7700 – a Premium 3T MRI system with seamless integration of multi-nuclei, and the Philips Portable Ultrasound Compact 5000 Series, with enhanced scanning time and power-up capability. 7. The Company's global innovation strengths at Bangalore (PIC) and global design and manufacturing capabilities at Pune (HIC) are contributing to the success of "Make in India" medical equipment. 8. The Affiniti series of Ultrasounds (Affiniti 30, Affiniti 50, Affiniti 70) manufactured in India are significant contributors to Philips Ultrasound business in the country. 9. Personal Health business delivered a marginal growth of 7.5%* over the previous financial year despite a volatile and dynamic macro environment. This growth was delivered in a highly competitive environment with low-cost players and challenges due to increase in cost trends of the commodities and adverse currency fluctuations. https://unlistedzone.com/shares/buy-sell-share-price-philips-india-limited-unlisted-shares/
Indicative prices, company research and your enquiries — in your pocket. Get price notes on the names you follow and reach our team from anywhere.
